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Abstract 
Background: Interleukin (IL)-18 gene polymorphisms have been found to play multiple roles in various diseases. 
However, studies focused on its involvement in hepatocellular carcinoma (HCC) remains controversial, and no much 
study has taken IL-18 serum levels into consideration. This study investigates the association between IL-18 polymor-
phisms and risk of hepatitis B virus-related HCC and their impact on serum IL-18 serum levels.
Methods: A total of 153 patients and 165 healthy controls were enrolled in this study. Polymorphisms at positions 
−607C/A and −137G/C in the IL-18 gene were determined using the polymerase chain reaction-restriction fragment 
length polymorphism method. Serum IL-18 levels were determined with an ELISA kit.
Results: No relationship was found between the −607C/A polymorphism and an individual’s susceptibility to 
HCC. For the −137G/C polymorphism, the GC genotype and C allele were found to be significantly associated with 
decreased HCC risk (OR 0.506, 95% CI 0.290–0.882, P = 0.016 and OR 0.520, 95% CI 0.332–0.814, P = 0.004, respec-
tively). The A−607C−137 haplotype was also associated with a significant decreased risk of HCC (OR 0.495, 95% CI 
0.294–0.834, P = 0.007). Serum IL-18 levels were found to be significantly lower in HCC patients compared to the 
control group in both the overall population and subjects with the different SNPs. Further, no association was found 
between serum IL-18 levels and the different genotypes within the same SNP.
Conclusion: These findings suggest that the −137G/C SNP in IL-18 may be a protective factor against HCC. Never-
theless, none of the studied SNPs was associated with the expression of IL-18.
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Background
Hepatitis B virus (HBV) infection is highly prevalent and 
one of the major causes of morbidity and death world-
wide. Globally, two billion people have been reported to 
be infected with HBV, of which approximately one-fifth 
(about 350–400 million) are chronic carriers; further, 
tens of millions of new HBV cases occur annually [1]. 
The outcome of chronic HBV infection is highly variable, 
ranging from an asymptomatic carrier state with a nor-
mal liver histology to persistent carriers with severe and 
chronic liver diseases such as cirrhosis and hepatocellu-
lar carcinoma (HCC) [2]. HCC is the fifth most frequent 
cancer in men and the seventh in women worldwide [3], 
and ranks as the second most common malignancy in 
China, especially in Southern Guangxi [4]. Among indi-
viduals persistently infected with HBV, one to three in 
every ten will develop liver cirrhosis and HCC [5]. Such 
highly variable outcomes may be generally attributed to 
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viral factors such as HBV infection [6] and environmen-
tal factors such as dietary aflatoxin B1 exposure [7], along 
with an individual’s immunological status and genetic 
background [8]. Further, according to Peng et al. [9], the 
morbidity of HCC can be distinct in individuals with the 
same exposure, suggesting that host immunological sta-
tus and genetic factors may play important roles in the 
development of HBV-related HCC.
Interleukin-18 (IL-18), a novel proinflammatory 
cytokine belonging to the IL-1 cytokine super-family, 
is mainly produced by activated macrophages and can 
mediate both innate and adaptive immunity [10, 11]. 
It was initially recognized as an interferon-γ (IFN-γ)-
inducing factor [12] and has a wide range of functions, 
including induction of the synthesis of IFN-γ in T cells 
and natural killer cells through synergistic action with 
IL-12 and IL-10, respectively [13–15], promotion of Th1-
type immune responses, and enhancement of the prolif-
erative response and cytokine production of activated T 
cells [16]. Recently, this cytokine was found to play vari-
ous roles in chronic inflammation [17] and autoimmune 
diseases, as well as in numerous infectious diseases [18–
20]. Further, IL-18 has been linked to acute liver injury 
[21]. As HCC is a typical inflammation-related can-
cer, these biologic effects of IL-18 might thus be impli-
cated with HCC development, suggesting that abnormal 
expression of IL-18 could be associated with the patho-
genesis of this disease.
The human IL-18 gene is located on chromo-
some 11q22.2-22.3 and consists of six exons and five 
introns [22]. So far, three single nucleotide polymor-
phisms (SNPs) in the promoter region of the IL-18 gene 
have been elucidated, namely −656G/T (rs1946518), 
−607C/A (rs1946519), and −137G/C (rs187238) [23]. A 
change from the C to the A allele at position −607C/A 
and a change from the G to the C allele at position 
−137G/C in the promoter region were predicted to be 
the nuclear factor binding sites for the cAMP respon-
sive element binding protein and H4TF-1 nuclear fac-
tor, respectively. Furthermore, polymorphisms of the 
two sites have been associated with IL-18 gene promoter 
transcription activity, which can influence the expres-
sion of IL-18 and, potentially, of IFN-γ [23, 24]; these 
allelic changes may be the underlying mechanism of IL-
18 involvement in various diseases. To date, IL-18 poly-
morphisms have been proved associated with various 
diseases, including chronic HBV infection [17], systemic 
lupus erythematosus [25], breast cancer [26], oral can-
cer [27, 28], thyroid cancer [29], colorectal cancer [30], 
and bladder cancer [31]. However, results focused on 
the effect of IL-18 polymorphisms or IL-18 expression 
on the risk of HBV-related HCC remains controversial 
[32–34], and no much study has taken IL-18 serum levels 
into consideration. The present study was performed in 
order to further investigate the possible role of IL-18 
−607C/A and −137G/C polymorphisms on the suscep-
tibility to HBV-related HCC and their impact on serum 
IL-18 serum levels. This study compares IL-18 polymor-
phisms and IL-18 serum levels between HBV-related 
HCC patients and healthy controls from Guangxi, China, 
a region with a high HBV prevalence.
Methods
Patients and controls
The study includes 153 HBV-related HCC patients and 
165 healthy controls, of which were estimated using 
Quanto software (version 1.2.4). We assumed that the 
prevalence of the−607C/A (rs1946519) AA genotype in 
the control group was 38.1% (according to HapMap Pro-
ject dbSNP database: http://www.ncbi.nlm.nih.gov/snp/, 
the HCB population), and estimated OR was 2.0 with 
probability of α = 0.05, β = 0.1 and matched case–con-
trol design. According to the parameters set, the calcula-
tion result was 136, a sample size with 153 cases and 165 
controls was therefore considered had enough power to 
evaluate the risk of the IL-18 genetic variation on HCC 
development. All participants were recruited from the 
First Affiliated Hospital of Guangxi Medical University 
between May and December 2013. Inclusion criteria for 
the HCC group were as follows: (1) All patients were 
seropositive to hepatitis B surface antigen, HBV core 
antibody, hepatitis Be antigen, or hepatitis Be antibody 
for at least 6 months; (2) newly diagnosed HCC patients 
with positive cytologic or pathologic findings for HCC; 
and (3) without other hepatitis virus infections such 
as hepatitis C or hepatitis E. The control age-, sex- and 
ethnic- matched subjects were randomly selected from 
the same hospital and confirmed to be HBV free and 
without any malignancy or other serious illness. Other 
demographic and laboratory data such as smoking hab-
its, alcohol consumption (both defined as never and 
current), level of alanine aminotransferase (ALT), and 
aspartate aminotransferase (AST) were obtained using 
electronic medical records. Informed consent for genetic 
analysis was obtained from all participants. The study 
was approved by the ethics committee of the First Affili-
ated Hospital of Guangxi Medical University.
Determination of the IL‑18 genotypes
About 2 mL peripheral blood samples in ethylenediami-
netetraacetic acid (EDTA)-coated vials were collected 
from all of the participants and stored at −80°C until 
use. Genomic DNA was extracted using a QIAamp DNA 
blood mini kit (QIAGEN GmbH, Hilden, Germany). 
Amplification of the target DNA was performed by poly-
merase chain reaction (PCR). IL-18 gene polymorphisms 
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at positions −607C/A and −137G/C were identified 
using PCR-restriction fragment length polymorphism. 
The primer sequences, annealing temperature, restric-
tion enzymes used, and length of the PCR products are 
shown in Table 1. To confirm the genotyping results, 32 
samples (about 10%) were randomly selected and directly 
sequenced by Sangon Biotech Company with an ABI 
Prism 3100 (Shanghai, China). A 100% concordance rate 
was achieved.
Serum IL‑18 levels
Serum samples without any anticoagulation were col-
lected for all cases and controls. Following the obtain-
ment of blood specimens, the serum was allowed to clot 
for 30 min at room temperature before centrifugation at 
2,000 rpm for 10 min at 4°C. The serum was then isolated 
and stored at −80°C until further use. A sandwich ELISA 
kit (Human Interleukin 18 ELISA Kit, Sangon Biotech 
Company, Shanghai, China) was used, according to the 
manufacturer’s instructions, to determine IL-18 serum 
levels for all subjects. The minimum level of detection for 
IL-18 was 15 ng/L. Each sample was assayed in duplicate 
and the intra-assay coefficient of variation was 7.5%.
Statistical analysis
We used the Student’s t test and the χ2 test to evaluate 
the distribution of the general demographic and clinical 
features between cases and controls. The Hardy-Wein-
berg equilibrium (HWE) was tested via a goodness-of-fit 
χ2 test with 1° of freedom to compare the observed geno-
type frequencies among the subjects with the expected 
genotype frequencies. Allele frequency and genotype dis-
tribution of IL-18 gene polymorphisms were compared 
using the χ2 test and Fisher’s exact test, as appropriate. 
The association between the genotypes and HCC risk was 
estimated by odds ratios (ORs) with corresponding 95% 
confidence intervals (CIs) calculated using the binary 
logistic regression model and were further adjusted for 
age, sex, smoking, and alcohol consumption status. Hap-
lotypes and their frequencies were also estimated based 
on a Bayesian algorithm with the Phase program [35]. For 
serum IL-18 levels, means and standard deviations (SD) 
were used to express the data if variables were normally 
distributed, if not, they were described as median and 
interquartile range. One-way ANOVA or the Kruskal–
Wallis test were used to examine the difference of serum 
IL-18 levels in different genotypes with the same group 
subjects, in  situations of normal or skewed distribu-
tion, respectively; if significant, these were followed by 
the Student–Newman–Keuls test. The Student’s t-test 
or Mann–Whitney U-test were used to examine the dif-
ference in serum IL-18 levels between the two groups 
among individuals with the same genotype, in situations 
of normal or skewed distribution, respectively. All statis-
tical analyses were performed using the statistical soft-
ware package SPSS 16.0 (SPSS Inc., Chicago, IL, USA), 
with two-sided P values <0.05 being considered as statis-
tically significant.
Results
Clinical characteristics of the study subjects
The demographic and clinical characteristics of the cases 
and control subjects are shown in Table 2. The mean ages 
(SD) in the control and patient groups were 47.37 ± 11.55 
and 49.18 ±  11.36, respectively, with no significant dif-
ference between them. Further, there were no significant 
differences in sex, smoking, or alcohol consumption sta-
tus, suggesting that the case data were comparable with 
those of the controls (all P > 0.05). However, the values of 
ALT and AST were significantly higher in HCC patients 
than in controls (both p < 0.001)
Association between −607C/A SNP and HBV‑related HCC 
risk
The genotype and allele frequencies of IL-18 −607C/A 
polymorphisms in the HBV-related HCC patients and 
healthy controls are shown in Table 3. According to the 
HWE test, the genotype distribution of this SNP in con-
trols were within HWE (P =  0.322). The frequencies of 
the AA, AC, and CC genotypes of −607C/A were 24.8, 
46.1, and 29.1%, respectively, in healthy controls and 
24.2, 47.7, and 28.1%, respectively, in HBV-related HCC 
Table 1 Primer sequences and reaction conditions for genotyping IL-18 polymorphisms
Polymorphisms Primer sequence Annealing temperature Restriction enzyme Product size (bp)
−607C/A F:5′-TCAGTGGAACAGGAGTCCAT-3′ 50°C DraI AA: 109 + 41
R:5′-GCAGAAAGTGTAAAAATTTTT-3′ CC: 150
AC: 109 + 41 + 150
−137G/C F:5′-AGGTGCTTTCTTAAAGTCAGA-3′ 50°C HinfI GG: 107 + 42
R:5′-AATATCACRATTTTCATGGAA-3′ CC: 149
GC: 107 + 42 + 149
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patients. No significant differences were observed in the 
genotype distributions of this polymorphism between the 
patient and control groups. Logistic regression analyses 
adjusted for age, sex, smoking, and alcohol consumption 
status revealed that the −607C/A AC and CC genotypes 
were not associated with HCC risk compared with the 
AA genotype (P = 0.799 and P = 0.943). Similar results 
were observed when comparing the C allele carriers with 
the reference A allele carriers (P = 0.968).
Association between −137G/C SNP and HBV‑related HCC 
risk
The genotype and allele frequencies of the IL-18 
−137G/C polymorphism among the patient and healthy 
subject groups are presented in Table  3. The goodness-
of-fit χ2 test revealed that the genotype frequencies of 
this SNP in controls were also consistent with the HWE 
(P = 0.548). The frequencies of the GG, GC, and CC were 
64.3, 32.7, and 3.0%, respectively, in healthy controls and 
79.7, 18.3, and 2.0%, respectively, in HBV-related HCC 
patients. Significant differences in the genotype dis-
tributions of this polymorphism among patients with 
HBV-related HCC and control subjects were observed 
(P = 0.008). Further, logistic regression analyses adjusted 
for age, sex, smoking, and alcohol consumption status 
found that the GC genotype was significantly associated 
with HCC risk compared with the GG genotype (OR: 
0.506, 95% CI: 0.290–0.882, P = 0.016). With regards to 
the −137G/C SNP alleles, significant differences in the C 
allele distribution were noted when compared with the 
reference G allele (P = 0.004); logistic regression analyses 
revealed that the C allele was associated with a reduced 
risk of HBV-related HCC (OR 0.520, 95% CI 0.332–0.814, 
P = 0.004; Table 3).
Haplotype analyses of IL‑18 SNPs and HCC risk
Haplotype analyses were further performed in HBV-
related HCC patients and healthy controls using the 
SHEsis software, in order to evaluate the haplotype 
Table 2 Clinical characteristic of the study subjects
ALT alanine aminotransferase, AST aspartate aminotransferase, SD standard 
deviation.
Variable Cases, n = 153 (%) Controls, n = 165 (%) P
Age (mean ± SD) 49.18 ± 11.36 47.37 ± 11.55 0.836
Sex
 Male 134 (87.6) 143 (86.7) 0.808
 Female 19 (12.4) 22 (13.3)
Ethnic(Han/Zhuang) 92/61 102/63 0.758
Alcohol consumption
 No 112 (73.2) 120 (72.7) 0.924
 Yes 41 (26.8) 45 (27.3)
Cigarette smoking
 No 118 (77.1) 125 (75.8) 0.774
 Yes 35 (22.9) 40 (24.2)
ALT(mean ± SD) 56.42 ± 28.04 29.62 ± 6.85 0.001
AST(mean ± SD) 55.29 ± 28.47 30.12 ± 6.65 0.001
Table 3 The genotype and allele frequencies of IL-18 gene polymorphisms between HBV-HCC patients and controls
* P < 0.05.
a Values about genotype distribution.
b Adjusted by age, sex, smoking, and alcohol consumption status.
Polymorphisms Cases, n = 153 (%) Controls, n = 165 (%) χ2a P valuea ORb 95% CIb P valueb
−607C/A
 AA 37 (24.2) 41 (24.8) 0.088 0.957 1.0ref 1.0ref
 AC 73 (47.7) 76 (46.1) 1.075 0.615–1.881 0.799
 CC 43 (28.1) 48 (29.1) 1.024 0.534–1.963 0.943
 A allele 147 (48.0) 158 (47.9) 0.957 0.968 1.0ref 1.0ref
 C allele 159 (52.0) 172 (52.1) 1.006 0.737–1.374 0.968
 P-HWE 0.584 0.322
−137G/C
 GG 122 (79.7) 106 (64.3) 9.468 0.008* 1.0ref 1.0ref
 GC 28 (18.3) 54 (32.7) 0.506 0.290–0.882 0.016
 CC 3 (2.0) 5 (3.0) 0.813 0.173–3.802 0.792
 G allele 272 (88.9) 266 (80.6) 8.357 0.004* 1.0ref 1.0ref
 C allele 34 (11.1) 64 (19.4) 0.520 0.332–0.814 0.004*
 P-HWE 0.363 0.548
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frequencies of polymorphisms located in the same 
chromosome regions and to derive haplotypes spe-
cifically correlated with HCC. Four possible haplotypes 
(A−607C−137, A−607G−137, C−607C−137, C−607G−137) were 
derived from the observed genotypes; their distributions 
in both groups are shown in Table 4. The results showed 
that the major C−607G−137 haplotype appeared in 48.4% 
and 47.0% of cases in the patient and control groups, 
respectively. Using haplotype analyses, the A−607C−137 
haplotype was observed to be associated with a signifi-
cantly decreased risk of HCC (OR 0.495; 95% CI 0.294–
0.834; P  =  0.007). The remaining haplotypes were not 
associated with HCC risk.
Association between IL‑18 gene polymorphisms and serum 
IL‑18 levels
Serum IL-18 levels showed a markedly skewed distribu-
tion and were therefore expressed as the median ± inter-
quartile range (Table 5). Overall, the IL-18 concentration 
was significantly lower in HBV-related HCC patients 
(n = 153, 74.40 ± 45.20 ng/L) compared to the controls 
(n =  165, 112.48 ±  68.65 ng/L; P < 0.001). When com-
paring the difference in serum IL-18 levels between the 
two groups among individuals with the same genotype, 
a similar situation was found in which IL-18 levels in 
HBV-related HCC patients with the -607C/A AA, AC, 
and CC genotypes and −137G/C GG and GC genotypes 
were all significantly lower than in healthy control sub-
jects (all P < 0.05). No significant difference was observed 
in the −137G/C SNP CC genotype (P = 0.549), but this 
was mainly attributed to the limited number of subjects 
with this genotype (n =  3 and n =  5 in cases and con-
trols, respectively). With respect to the difference in 
serum IL-18 levels among different genotypes within the 
same group, null significant results were found in both 
case and control groups, indicating that the −607C/A 
and −137G/C polymorphisms in the IL-18 gene do not 
play a pivotal role in the expression of IL-18. Correlation 
analyses were further conducted to assess the associa-
tions between IL-18 levels with alanine aminotransferase 
(ALT) and aspartate aminotransferase (AST) in both 
patients and controls, similarly, insignificant results were 
found (patients: p =  0.810 and p =  0.909, respectively; 
controls: p = 0.460 and p = 0.304, respectively).
Discussion
HBV infection remains a public health problem world-
wide, being endemic in some regions of the world, espe-
cially in developing countries [36]. HBV can lead to 
severe liver diseases such as chronic hepatitis, cirrhosis, 
and HCC [37]. HBV-infected individuals are at a higher 
risk of developing HCC [38], and age, sex, alcohol con-
sumption, and smoking status are well known risk fac-
tors contributing to HCC incidence [39, 40]. However, 
these factors do not fully account for the underlying 
mechanisms in HCC development, indicating that the 
immune status of individuals may play pivotal roles in 
disease progression. Through its involvement in the pro-
inflammatory cytokine network, IL-18 is an important 
mediator of innate and adaptive immunity. Polymor-
phisms of this gene have been reported to influence the 
expression of IL-18 and may further lead to an altera-
tion in an individual’s immune status, thus increasing 







P OR 95% CI
A−607C−137 23 (7.5) 47 (14.2) 0.007* 0.495 0.294–0.834
A−607G−137 124 (40.5) 111 (33.6) 0.073 1.343 0.972–1.856
C−607C−137 11 (3.6) 17 (5.2) 0.324 0.674 0.306–1.483
C−607G−137 148 (48.4) 155 (47.0) 0.720 1.059 0.775–1.445
Table 5 The association between IL-18 gene polymorphisms and serum IL-18 levels (median ± interquartile range, ng/L) 
in HCC patients
a Kruskal–Wallis test: comparing the difference of serum IL-18 levels in different genotypes among the same group subjects.
b Mann–Whitney U-test: comparing the difference of serum IL-18 levels between the two group subjects among individuals with the same genotype.
Groups Overall −607C/A (rs1946518) −137G/C (rs187238)
AA AC CC P  
valuea
GG GC CC P  
valuea
Controls (n = 165) 112.48 ± 68.65 108.63 ± 105.14 
(41)
107.49 ± 71.25 
(76)
118.54 ± 46.25 
(48)
0.514 118.54 ± 66.47 
(106)
101.18 ± 63.20 
(54)
108.06 ± 99.24 
(5)
0.186
HCC (n = 153) 74.40 ± 45.20 77.48 ± 50.58 
(37)
76.33 ± 42.60 
(73)
67.10 ± 43.85 
(43)
0.202 74.69 ± 47.75 
(128)
69.21 ± 36.3 
(28)
71.33 ± 52.89 
(3)
0.942
P valueb <0.000 0.002 <0.000 <0.000 <0.000 <0.000 0.549
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carriers’ susceptibility to HCC development. However, 
this hypothesis is only partially confirmed herein.
In the present study, the IL-18 −137G/C polymor-
phism was observed to be significantly associated with 
HCC. The GC genotype and C allele of this SNP were 
associated with a significantly decreased risk of HCC 
compared with the GG genotype and G allele. Similarly, 
the A−607C−137 haplotype was significantly associated 
with a lower risk of HCC. Our findings were consistent 
with those of previous studies on IL-18 polymorphisms 
and HCC risk [32–34], all of which observed a signifi-
cant relationship between the −137G/C polymorphism 
and HCC risk, with a high G allele frequency being asso-
ciated with an increased risk of HCC and, conversely, a 
low C allele frequency being associated with a decreased 
risk of HCC. However, they also found a significantly 
increased frequency of the −607 C/A AA genotype in 
HCC patients (AC genotype in Kim et  al.’s study [32] ), 
while we observed a null association between them.
These controversial results may due to the underlying 
genetic differences between various populations. In a 
study investigating the relationship between HBV infec-
tion and IL-18 promoter polymorphisms among three 
minority populations in Yunnan province, China, the 
genotype and allele frequencies of all three SNPs in the 
IL-18 promoter (−607 C/A, −137G/C, and −656G/T) 
were found to have distinct distributions [41]. Fur-
ther, the authors observed a significant difference in 
HBV infection among the three minority populations, 
concluding that the difference in genetic background 
among the various ethnicities may be an important fac-
tor responsible for HBV infection susceptibility [41]. The 
present study was carried out in the Guangxi district, 
which is also ethnically diverse, and our study population 
contains both Han and Zhuang ethnicity—this may be 
the major contributing factor to the inconsistency result 
found in −607C/A polymorphism.
With regard to the serum IL-18 levels, they were found 
significantly lower in HCC patients compared to healthy 
subjects in the present study, such result is controversial 
to many studies. For instance, researches by Tangkijvan-
ich et al. [42] and Mohran et al. [43] showed that IL-18 
levels in HCC patients were significant higher than those 
in healthy controls, the latter study further concluded 
that serum IL-18 level was a suitable diagnostic marker 
in HCV-related HCC patients. However, though Wen 
et  al. [44] also observed significant differences in the 
transcription and expression levels of IL-18 among dif-
ferent HBV infector groups; interestingly, the highest was 
found in the fulminant hepatitis group and the lowest in 
the asymptomatic carrier group, and no significant differ-
ences between the chronic hepatitis and normal control 
groups were observed. These results indicate that serum 
IL-18 levels may be distinct at different disease stages. 
On the other hand, as all patients in our study were HBV-
related HCC, with hepatitis B surface antigen, HBV core 
antibody, hepatitis Be antigen, or hepatitis Be antibody 
seropositive for at least 6  months, the majority of them 
have gone through antiviral treatment; but, according to 
He et  al. [45], antiviral treatment (pegylated interferon 
alpha) can induce a marked decline in IL-18 and remis-
sion of hepatic inflammatory in HCV infectors. These 
may be the underlying factors for the inconsistent results 
observed herein.
Furthermore, no association between the two IL-18 
SNPs and IL-18 serum levels were observed in our study, 
which is inconsistent with previous reports. In the study 
conducted by Giedraitis et al. [23], three alleles from the 
IL-18 promoter region (at positions −656, −607, and 
−137) were cloned and transfected into a HeLa cell line, 
leading to a tenfold higher IL-18 gene fragment activity 
compared to the negative control. This indicated that 
all three polymorphisms had a clear promoting activ-
ity and were able to influence the expression of IL-18. 
However, Giedraitis et al. [23] only conducted studies on 
gene expression level, which were not fully representative 
of the transcription levels and, thus, of secretion levels. 
Therefore, our study is the first to show that −607 and 
−137 polymorphisms are not associated with the expres-
sion of IL-18 in serum. Nevertheless, since serum IL-18 
levels may be affected by various factors, some of these 
may mask the gene polymorphism effects.
In summary, the −137G/C polymorphism of the IL-
18 gene was observed to be significantly correlated with 
HCC risk. The A−607C−137 haplotype of the −607C/A 
and −137G/C SNPs was also associated with a decreased 
risk of HCC. These results indicate that the −137G/C 
SNP in IL-18 may be a protective factor against HCC. 
Further, lower serum IL-18 levels were found in HCC 
patients, however, the IL-18 −607C/A and −137G/C 
polymorphisms were not associated with IL-18 serum 
concentration. Considering the limited study population 
included herein, additional studies with larger samples 
and detailed clinical data are warranted in various ethnic 
populations.
Abbreviations
IL: interleukin; HCC: hepatocellular carcinoma; HBV: hepatitis B virus; IFN-γ: 
interferon-γ; SNPs: single nucleotide polymorphisms; PCR: polymerase chain 
reaction; HWE: Hardy–Weinberg equilibrium; ORs: odds ratios; CIs: confidence 
intervals; SD: standard deviations.
Authors’ contributions
YL, XH and LS carried out the molecular genetic studies, JB participated in the 
sequence alignment and and drafted the manuscript. CR and YqL participated 
in the design of the study and performed the statistical analysis. Shan Li and 
Xue Qin conceived of the study, and participated in its design and coordina-
tion and helped to draft the manuscript.
Page 7 of 8Bao et al. Cancer Cell Int  (2015) 15:72 
Acknowledgements
We thank Scribendi.com for its linguistic assistance during the preparation of 
this manuscript.
Compliance with ethical guidelines
Competing interests
The authors declare that they have no competing interests.
Received: 26 May 2015   Accepted: 7 July 2015
References
 1. Carey WD (2009) The prevalence and natural history of hepatitis B in the 
21st century. Clevel Clin J Med 76(Suppl 3):S2–S5. doi:10.3949/ccjm.76.
s3.01
 2. Shi YH, Shi CH (2009) Molecular characteristics and stages of chronic 
hepatitis B virus infection. World J Gastroenterol : WJG. 15(25):3099–3105
 3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global 
cancer statistics. CA Cancer J Clin 61(2):69–90. doi:10.3322/caac.20107
 4. Chen JG, Zhang SW (2011) Liver cancer epidemic in China: past, 
present and future. Semin Cancer Biol 21(1):59–69. doi:10.1016/j.
semcancer.2010.11.002
 5. Zeng Z (2014) Human genes involved in hepatitis B virus infection. World 
J Gastroenterol WJG 20(24):7696–7706. doi:10.3748/wjg.v20.i24.7696
 6. Boni C, Penna A, Ogg GS, Bertoletti A, Pilli M, Cavallo C et al (2001) Lami-
vudine treatment can overcome cytotoxic T-cell hyporesponsiveness in 
chronic hepatitis B: new perspectives for immune therapy. Hepatology 
(Baltimore, Md) 33(4):963–971. doi:10.1053/jhep.2001.23045
 7. Sun Z, Lu P, Gail MH, Pee D, Zhang Q, Ming L et al (1999) Increased risk of 
hepatocellular carcinoma in male hepatitis B surface antigen carriers with 
chronic hepatitis who have detectable urinary aflatoxin metabolite M1. 
Hepatology (Baltimore, Md) 30(2):379–383. doi:10.1002/hep.510300204
 8. Chisari FV (1997) Cytotoxic T cells and viral hepatitis. J Clin Investig 
99(7):1472–1477. doi:10.1172/jci119308
 9. Tao P, Zhi-Ming L, Tang-Wei L, Le-Qun L, Min-Hao P, Xue Q et al (2005) 
Associated factors in modulating aflatoxin B1-albumin adduct level in 
three Chinese populations. Dig Dis Sci 50(3):525–532
 10. Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H (2001) Interleukin-18 
regulates both Th1 and Th2 responses. Annu Rev Immunol 19:423–474. 
doi:10.1146/annurev.immunol.19.1.423
 11. Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H (2001) Interleukin-18 is a 
unique cytokine that stimulates both Th1 and Th2 responses depending 
on its cytokine milieu. Cytokine Growth Factor Rev 12(1):53–72
 12. Okamura H, Tsutsi H, Komatsu T, Yutsudo M, Hakura A, Tanimoto T et al 
(1995) Cloning of a new cytokine that induces IFN-gamma production by 
T cells. Nature 378(6552):88–91. doi:10.1038/378088a0
 13. Yoshimoto T, Takeda K, Tanaka T, Ohkusu K, Kashiwamura S, Okamura 
H et al (1998) IL-12 up-regulates IL-18 receptor expression on T cells, 
Th1 cells, and B cells: synergism with IL-18 for IFN-gamma production. J 
Immunol (Baltimore, Md: 1950) 161(7):3400–3407
 14. Tominaga K, Yoshimoto T, Torigoe K, Kurimoto M, Matsui K, Hada T et al 
(2000) IL-12 synergizes with IL-18 or IL-1beta for IFN-gamma production 
from human T cells. Int Immunol 12(2):151–160
 15. Cai G, Kastelein RA, Hunter CA (1999) IL-10 enhances NK cell pro-
liferation, cytotoxicity and production of IFN-gamma when com-
bined with IL-18. Eur J Immunol 29(9):2658–2665. doi:10.1002/
(sici)1521-4141(199909)29:09<2658:aid-immu2658>3.0.co;2-g
 16. Micallef MJ, Ohtsuki T, Kohno K, Tanabe F, Ushio S, Namba M et al 
(1996) Interferon-gamma-inducing factor enhances T helper 1 cytokine 
production by stimulated human T cells: synergism with interleukin-12 
for interferon-gamma production. Eur J Immunol 26(7):1647–1651. 
doi:10.1002/eji.1830260736
 17. Zhang PA, Wu JM, Li Y, Yang XS (2005) Association of polymorphisms of 
interleukin-18 gene promoter region with chronic hepatitis B in Chinese 
Han population. World J Gastroenterol WJG 11(11):1594–1598
 18. Gillespie MT, Horwood NJ (1998) Interleukin-18: perspectives on the new-
est interleukin. Cytokine Growth Factor Rev 9(2):109–116
 19. Gracie JA, Robertson SE, McInnes IB (2003) Interleukin-18. J Leukoc Biol 
73(2):213–224
 20. Gracie JA, Forsey RJ, Chan WL, Gilmour A, Leung BP, Greer MR et al (1999) 
A proinflammatory role for IL-18 in rheumatoid arthritis. J Clin Investig 
104(10):1393–1401. doi:10.1172/jci7317
 21. Tsutsui H, Kayagaki N, Kuida K, Nakano H, Hayashi N, Takeda K et al (1999) 
Caspase-1-independent, Fas/Fas ligand-mediated IL-18 secretion from 
macrophages causes acute liver injury in mice. Immunity 11(3):359–367
 22. Kruse S, Kuehr J, Moseler M, Kopp MV, Kurz T, Deichmann KA et al (2003) 
Polymorphisms in the IL 18 gene are associated with specific sensitiza-
tion to common allergens and allergic rhinitis. J Allergy Clin Immunol 
111(1):117–122
 23. Giedraitis V, He B, Huang WX, Hillert J (2001) Cloning and mutation 
analysis of the human IL-18 promoter: a possible role of polymorphisms 
in expression regulation. J Neuroimmunol 112(1–2):146–152
 24. Arimitsu J, Hirano T, Higa S, Kawai M, Naka T, Ogata A et al (2006) IL-18 
gene polymorphisms affect IL-18 production capability by monocytes. 
Biochem Biophys Res Commun 342(4):1413–1416. doi:10.1016/j.
bbrc.2006.02.096
 25. Lin YJ, Wan L, Lee CC, Huang CM, Tsai Y, Tsai CH et al (2007) Disease asso-
ciation of the interleukin-18 promoter polymorphisms in Taiwan Chinese 
systemic lupus erythematosus patients. Genes Immun 8(4):302–307. 
doi:10.1038/sj.gene.6364387
 26. Taheri M, Hashemi M, Eskandari-Nasab E, Fazaeli A, Arababi F, Bahrani-
Zeidabadi M et al (2012) Association of -607 C/A polymorphism of IL-18 
gene (rs1946518) with breast cancer risk in Zahedan, Southeast Iran. 
Prague Med Rep 113(3):217–222
 27. Tsai HT, Hsin CH, Hsieh YH, Tang CH, Yang SF, Lin CW et al (2013) Impact 
of interleukin-18 polymorphisms -607A/C and -137G/C on oral cancer 
occurrence and clinical progression. PLoS One 8(12):e83572. doi:10.1371/
journal.pone.0083572
 28. Vairaktaris E, Serefoglou ZC, Yapijakis C, Agapi C, Vassiliou S, Nkenke E et al 
(2007) The interleukin-18 -607A/C polymorphism is not associated with 
risk for oral cancer. Anticancer Res 27(6B):4011–4014
 29. Cunha LL, Tincani AJ, Assumpcao LV, Soares FA, Vassallo J, Ward LS 
(2011) Interleukin-10 but not interleukin-18 may be associated with the 
immune response against well-differentiated thyroid cancer. Clinics (Sao 
Paulo, Brazil) 66(7):1203–1208
 30. Nikiteas N, Yannopoulos A, Chatzitheofylaktou A, Tsigris C (2007) Het-
erozygosity for interleukin-18 -607 A/C polymorphism is associated with 
risk for colorectal cancer. Anticancer Res 27(6B):3849–3853
 31. Jaiswal PK, Singh V, Srivastava P, Mittal RD (2013) Association of IL-12, 
IL-18 variants and serum IL-18 with bladder cancer susceptibility in North 
Indian population. Gene 519(1):128–134. doi:10.1016/j.gene.2013.01.025
 32. Kim YS, Cheong JY, Cho SW, Lee KM, Hwang JC, Oh B et al (2009) A func-
tional SNP of the Interleukin-18 gene is associated with the presence of 
hepatocellular carcinoma in hepatitis B virus-infected patients. Dig Dis Sci 
54(12):2722–2728. doi:10.1007/s10620-009-0970-6
 33. Migita K, Sawakami-Kobayashi K, Maeda Y, Nakao K, Kondoh S, Sugiura 
M et al (2009) Interleukin-18 promoter polymorphisms and the disease 
progression of Hepatitis B virus-related liver disease. Transl Res J Lab Clin 
Med 153(2):91–96. doi:10.1016/j.trsl.2008.11.008
 34. Chen Q, Liao WJ, He SQ, Yuan SG, Qin LL, Yu YQ, Mei HM (2012) The 
correlation between single nucleotide polymorphism of interleukin-18 
gene promoter and genetic susceptibility to hepatocellular carcinoma. 
Immunol J 28(12):1051–1055
 35. Stephens M, Smith NJ, Donnelly P (2001) A new statistical method 
for haplotype reconstruction from population data. Am J Hum Genet 
68(4):978–989. doi:10.1086/319501
 36. Liaw YF, Chu CM (2009) Hepatitis B virus infection. Lancet 373(9663):582–
592. doi:10.1016/s0140-6736(09)60207-5
 37. Chisari FV, Ferrari C (1995) Hepatitis B virus immunopathogenesis. Annu 
Rev Immunol 13:29–60. doi:10.1146/annurev.iy.13.040195.000333
 38. Bosetti C, Levi F, Boffetta P, Lucchini F, Negri E, La Vecchia C (2008) Trends 
in mortality from hepatocellular carcinoma in Europe, 1980–2004. Hepa-
tology (Baltimore, Md) 48(1):137–145. doi:10.1002/hep.22312
 39. Boffetta P, Hashibe M, La Vecchia C, Zatonski W, Rehm J (2006) The burden 
of cancer attributable to alcohol drinking. Int J Cancer (J international du 
cancer) 119(4):884–887. doi:10.1002/ijc.21903
 40. Bosch FX, Ribes J, Diaz M, Cleries R (2004) Primary liver cancer: worldwide 
incidence and trends. Gastroenterology 127(5 Suppl 1):S5–S16
Page 8 of 8Bao et al. Cancer Cell Int  (2015) 15:72 
 41. Gao JM, Zou YL, Dong H, Tang H, Xu Y, Yan XM (2010) Relationship 
between HBV infection and polymorphism of IL-18 promoter gene 
among three minority populations in Yunnan province. China J Clin 
4(9):1525–1531
 42. Tangkijvanich P, Thong-Ngam D, Mahachai V, Theamboonlers A, Poo-
vorawan Y (2007) Role of serum interleukin-18 as a prognostic factor 
in patients with hepatocellular carcinoma. World J Gastroenterol WJG 
13(32):4345–4349
 43. Mohran ZY, Ali-Eldin FA, Abdel Aal HA (2011) Serum interleukin-18: does it 
have a role in the diagnosis of hepatitis C virus related hepatocellular car-
cinoma? Arab J Gastroenterol 12(1):29–33. doi:10.1016/j.ajg.2010.11.002
 44. Wen W, Zhang L, Xiao H (2001) The transcription and expression of IL-18 
gene in HBV infectors. Zhonghua yi xue za zhi. 81(11):655–658
 45. YingLi H, Shumei L, Qian Y, Tianyan C, Yingren Z, Wei C (2009) Proa-
poptotic IL-18 in patients with chronic hepatitis C treated with 
pegylated interferon-alpha. Clin Exp Med 9(2):173–178. doi:10.1007/
s10238-009-0041-5
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
